Correlation between Statin Solubility and Mortality in Patients on Chronic Hemodialysis

• Published in: Diagnostics (Basel) Vol. 13; no. 20; p. 3290
• Main Authors: Kang, Seok-Hui, Kim, Gui-Ok, Kim, Bo-Yeon, Son, Eun-Jung, Do, Jun-Young
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: Analysis; Blood pressure; Cardiovascular disease; Clinical outcomes; Clopidogrel; Datasets; Diabetes; Disease prevention; Drug dosages; Endocrine system; Heart diseases; Hemodialysis; Kidney diseases; Kidney transplants; Liver diseases; Medical prognosis; Mortality; Patient outcomes; Patients; Peritoneal dialysis; solubility; statin; Statins; South Korea
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13203290

This study aimed to evaluate the effect of statin solubility on the survival of patients undergoing hemodialysis (HD). This retrospective study used laboratory and clinical data from a national HD quality assessment program and claims data (n = 53,345). The use of statins was defined as prescription ≥30 days during 6 months of each HD quality assessment period. We divided the patients into three groups based on the use and solubility of statins: No group, patients without a prescription of statins (n = 37,944); Hydro group, patients with a prescription of hydrophilic statins (n = 2823); and Lipo group, patients with a prescription of lipophilic statins (n = 12,578). The 5-year survival rates in the No, Hydro, and Lipo groups were 69.6%, 67.9%, and 67.9%, respectively (p < 0.001 for the trend). Multivariable Cox regression analyses showed that the Lipo group had better patient survival than the No group. However, multivariable analyses did not show statistical significance between the Hydro and No or Lipo groups. In all subgroups based on sex, age, presence of diabetes mellitus, and heart disease, the Lipo group had better patient survival than the No group. We identified no significant association between hydrophilic and lipophilic statins and patient survival. However, patients taking lipophilic statins had a modest survival benefit compared with those who did not receive statins.